| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:27803384 | IVR | 200 mg/kg/day | 200 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.